Your browser doesn't support javascript.
loading
Projected Public Health Impact of a Universal Rotavirus Vaccination Program in France.
Oluwaseun, Sharomi; Cagnan, Lauren; Xausa, Ilaria; Nachbar, Robert B; Levy Bachelot, Laurie; Chen, Yao-Hsuan; Carias, Cristina.
Affiliation
  • Oluwaseun S; From the BARDS-HEDS Department, Merck & Co., Inc, Rahway, NJ.
  • Cagnan L; Market Access Department, MSD France, Courbevoie Cedex, France.
  • Xausa I; Wolfram Solutions Department, Wolfram Research Inc, Champaign, IL.
  • Nachbar RB; Wolfram Solutions Department, Wolfram Research Inc, Champaign, IL.
  • Levy Bachelot L; CORE Regional, MSD France, Courbevoie Cedex, France.
  • Chen YH; MSD (UK) Limited, BARDS-HEDS, London, United Kingdom.
  • Carias C; Merck & Co., Inc, CORE PL, Rahway, NJ.
Pediatr Infect Dis J ; 43(9): 902-908, 2024 09 01.
Article in En | MEDLINE | ID: mdl-39163534
ABSTRACT

OBJECTIVE:

In June 2022, French health authorities issued a universal recommendation for routine administration and reimbursement of rotavirus vaccines in infants. Given this recent recommendation by French health authorities, we sought to understand the public health impact of a universal rotavirus vaccination strategy compared with no vaccination. MATERIALS AND

METHODS:

A deterministic, age-structured, nonlinear dynamic transmission model, accounting for herd immunity, was developed. We considered 3 vaccination coverage scenarios high (95%), medium (75%) and low (55%). Model parameter values were based on published modeling and epidemiological literature. Model outcomes included rotavirus gastroenteritis (RVGE) cases and healthcare resource utilization due to RVGE (hospitalizations, general practitioner or emergency department visits), as well as the number needed to vaccinate to prevent 1 RVGE case (mild or severe) and 1 RVGE-related hospitalization. Model calibration and analyses were conducted using Mathematica 11.3.

RESULTS:

Over 5 years following implementation, RVGE cases for children under 5 years are estimated to be reduced by 84% under a high vaccination coverage scenario, by 72% under a medium vaccination coverage scenario and by 47% under a low vaccination coverage scenario. Across all scenarios, the number needed to vaccinate to avert 1 RVGE case and hospitalization varied between 1.86-2.04 and 24.15-27.44, respectively.

CONCLUSIONS:

Rotavirus vaccination with high vaccination coverage in France is expected to substantially reduce the number of RVGE cases and associated healthcare resource utilization.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rotavirus Infections / Public Health / Immunization Programs / Rotavirus Vaccines / Gastroenteritis Limits: Child, preschool / Humans / Infant / Newborn Country/Region as subject: Europa Language: En Journal: Pediatr Infect Dis J Journal subject: DOENCAS TRANSMISSIVEIS / PEDIATRIA Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rotavirus Infections / Public Health / Immunization Programs / Rotavirus Vaccines / Gastroenteritis Limits: Child, preschool / Humans / Infant / Newborn Country/Region as subject: Europa Language: En Journal: Pediatr Infect Dis J Journal subject: DOENCAS TRANSMISSIVEIS / PEDIATRIA Year: 2024 Document type: Article